Please assess the completion status of the following clinical trial:

Trial Title: Impact of Acthar on Everyday Life of Participants With Severe Keratitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has severe or recalcitrant keratitis~* Did not respond to, or tolerate, treatment with topical cyclosporine, Lifitegrast, or any immunosuppressant to treat keratitis~* If able to reproduce, agrees to use 2 forms of effective contraception with a partner of the opposite sex for the duration of the study (through Visit 6)~* Has normal eyelids, and protocol-defined physical and medical eye attributes~* Agrees to avoid wearing contact lenses during the trial~Exclusion Criteria:~* Is pregnant or breast-feeding~* Is defined as vulnerable, or is employed by, or related to anyone involved in the study~* Has a medical condition or history that might, per protocol or in the opinion of the investigator, compromise the participant's safety or study analysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All participants (Type: EXPERIMENTAL): Participants receive:~* a shot of Acthar (80 units) under the skin twice a week for 12 weeks~* a shot of Acthar (40 units) twice a week for 2 weeks~* a shot of Acthar (40 units) once a week for 2 more weeks~At each visit they will have medical tests and answer questions about their symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).